Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv Weeks'

Rbv Weeks published presentations and documents on DocSlides.

SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
Future HCV Treatment Paradigms
Future HCV Treatment Paradigms
by kittie-lecroy
Mark Sulkowski, MD . Professor of Medicine. Medic...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
C-SCAPE
C-SCAPE
by pasty-toler
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
by tatiana-dople
dans les génotypes 1b naïfs de traitement . (1)...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
C-SCAPE
C-SCAPE
by tawny-fly
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Elbasvir
Elbasvir
by calandra-battersby
+ . Grazoprevir. +/- Ribavirin in . Treatment-N...
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
Forns
Forns
by ellena-manuel
X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE ...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...